Seeking Alpha
 

Pfizer Inc. (PFE)

- NYSE
  • Aug. 7, 2012, 12:31 PM
    Pfizer (PFE -1.7%) reaches a settlement with the DOJ and SEC regarding an investigation into improper payments in the operations of two of its foreign subsidiaries. To resolve the issues with both agencies, the company will pay a $15M fine, and disgorge $16M in profits along with $10.3M in interest. Its subsidiary Wyeth also reached a settlement on similar charges, agreeing to disgorge $17.2M in profits and $1.6M in interest.
    | Aug. 7, 2012, 12:31 PM | 1 Comment
  • Aug. 6, 2012, 5:55 PM
    Elan ELN, which has a 25% ownership stake in Pfizer (PFE) and Johnson & Johnson's failed bapineuzumab project, is also trading down after hours, along with Eli Lilly (LLY), who has a similar Alzheimer's candidate, solanezumab, for which clinical results are expected in coming weeks. ELN -8.7%, LLY -2.1%.
    | Aug. 6, 2012, 5:55 PM | Comment!
  • Aug. 6, 2012, 5:33 PM
    Johnson & Johnson (JNJ) down 1.6% and Pfizer (PFE) down 2.1% AH as the companies put a halt on studies of Alzheimer's drug bapineuzumab, which they were developing together but which left execs "disappointed."
    | Aug. 6, 2012, 5:33 PM | Comment!
  • Jul. 31, 2012, 10:27 AM
    Pfizer (PFE +2.4%) says during its earnings call that the FDA has requested additional analysis of existing data in its tofacitinib New Drug Application. The company plans to release this information in early August and, given this timing, it anticipates that FDA may require additional time beyond the August 21 PDUFA date to review.
    | Jul. 31, 2012, 10:27 AM | Comment!
  • Jul. 31, 2012, 8:03 AM
    More on Pfizer (PFE) Q2: net profit +25% to $3.25B despite a 9% fall in revenue following Lipitor's patent expiration, with the bottom line benefiting from major cost cuts. Pfizer plans to file to sell 20% of its animal health business, to be called Zoetis, in an IPO in mid-August. Shares +0.8% premarket.
    | Jul. 31, 2012, 8:03 AM | Comment!
  • Jul. 31, 2012, 7:03 AM
    Pfizer (PFE): Q2 EPS of $0.62 beats by $0.08. Revenue of $15.1B beats by $200M. (PR)
    | Jul. 31, 2012, 7:03 AM | 1 Comment
  • Jul. 31, 2012, 12:05 AM
    Notable earnings before Tuesday’s open: ADM, AET, BP, CIE, CMI, COH, DB, DISCA, DLPH, ECL, ETR, FWLT, GT, HCP, LPX, LQDT, MPC, NI, PEG, PFE, TIE, TRI, TRW, TYC, UBS, VLO, VSH, X, YNDX
    | Jul. 31, 2012, 12:05 AM | Comment!
  • Jul. 30, 2012, 5:30 PM
    Notable earnings before Tuesday’s open: ADM, AET, BP, CIE, CMI, COH, DB, DISCA, DLPH, ECL, ETR, FWLT, GT, HCP, LPX, LQDT, MPC, NI, PEG, PFE, TIE, TRI, TRW, TYC, UBS, VLO, VSH, X, YNDX
    | Jul. 30, 2012, 5:30 PM | Comment!
  • Jul. 30, 2012, 8:42 AM
    Acura Pharmaceuticals (ACUR) plummets 32% after news on Friday that Pfizer (PFE) has terminated the license to three development-stage drugs that use Acura’s technology.
    | Jul. 30, 2012, 8:42 AM | 2 Comments
  • Jul. 27, 2012, 4:51 PM
    Pfizer (PFE) says it's exercising its right to terminate the license and return three development stage products, oxycodone hydrochloride with acetaminophen, hydrocodone bitartrate with acetaminophen and another undisclosed opioid, to Acura Pharmaceutical (ACUR). A fourth product utilizing Acura's AVERSION Technology, Oxecta Tablets CII, is being commercialized, and Pfizer will retain all rights and obligations under the current license agreement.
    | Jul. 27, 2012, 4:51 PM | Comment!
  • Jul. 25, 2012, 11:46 AM
    Eli Lilly (LLY +2.7%) CEO John Lechleiter says to use caution when extrapolating the failed clinical trials of Pfizer (PFE -0.5%) and Johnson & Johnson's (JNJ +0.2%) Alzheimer's candidate, bapineuzumab, to solanezumab, the one that [LLY has in its pipeline. "We've got to be very careful before we draw conclusions," Lechleiter says. There are differences between the drugs, how they bond for example, that could allow for different outcomes. The company expects to report clinical data for solanezumab later in Q3.  (Video)
    | Jul. 25, 2012, 11:46 AM | Comment!
  • Jul. 23, 2012, 5:33 PM
    Pfizer (PFE) says an experimental Alzheimer's treatment it's working on with Johnson & Johnson (JNJ) unit Janssen Pharmaceuticals did not meet clinical endpoints in a late-stage study. In the study, patients with mild-to-moderate Alzheimer's disease given an intravenous form of the drug bapineuzumab didn't fare any better in cognitive and functional performance than those given a placebo. Elan (ELN), which holds a 49.9% equity interest in Janssen Alzheimer Immunotherapy, is taking a big hit after hours: PFE -1.3%, JNJ -0.2%, ELN -16.8%.
    | Jul. 23, 2012, 5:33 PM | 1 Comment
  • Jul. 23, 2012, 8:06 AM
    Pfizer's (PFE -0.9%) Lyrica nerve-pain drug didn't hurt reproductive function in healthy males in an FDA post-approval trial. Meanwhile, in a test for EU regulators of the medicine for treating generalized anxiety disorder, patients showed a low rate of symptoms as they tapered off from the drug after 3 and 6 months.
    | Jul. 23, 2012, 8:06 AM | Comment!
  • Jul. 19, 2012, 5:16 PM
    Pfizer (PFE) says that it's won its LYRICA patent case relating to pain and seizure use patents covering LYRICA capsules. Under the ruling PFE will exclusively provide pregabalin as LYRICA to patients, subject to further generic company appeals and litigation. Shares +0.5% AH.
    | Jul. 19, 2012, 5:16 PM | Comment!
  • Jul. 17, 2012, 3:31 PM
    A 4.1% dividend rate on a regulated utility selling at a 15 PE may look attractive, writes Martin Sosnoff, but payout ratios are nearly 70% of slow-growing earnings. Instead take a look at healthcare, yielding a similar amount but with lower payout ratios. His favorites are BMY, MRK, PFE, and UNH. Of note, the XLV hit an all-time high today.
    | Jul. 17, 2012, 3:31 PM | 2 Comments
  • Jul. 11, 2012, 4:42 AM
    Shionogi-ViiV Healthcare, a JV involving GSK, Pfizer (PFE) and Shionogi, says a Phase III trial of its dolutegravir HIV treatment suggests it might be more effective than Gilead's (GILD) and Bristol-Myers Squibb's (BMY) Atripla drug. GSK shares +0.3% in London. (PR)
    | Jul. 11, 2012, 4:42 AM | Comment!
Visit Seeking Alpha's
PFE vs. ETF Alternatives
Company Description
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.